Introduction {#s1}
============

Myotonic dystrophy type 1 (DM1; OMIM\#[160900](160900)) and type 2 (DM2; OMIM\#[602668](602668)) are dominantly inherited neuromuscular disorders characterized by a multisystemic involvement including muscle weakness, myotonia, respiratory insufficiency, central nervous system impairment, conduction system disease, ventricular dysfunction, and supraventricular and ventricular arrhythmias ([@B1]). DM1 is caused by an expanded CTG repeat in the 3′ untranslated region (UTR) of the *Dystrophia Myotonic Protein Kinase* gene (*DMPK*) ([@B2]--[@B4]), while DM2 is caused by expanded CCTG repeats in intron 1 of the *CCHC-type zinc finger, Nucleic acid Binding Protein* gene (*CNBP*/*ZNF9*) ([@B5]). Nuclear accumulation of CUG/CCUG-containing RNA is thought to be toxic, contributing significantly to pathogenesis since the deregulation of several splicing factors, leading to the alteration of alternative splicing of various genes linked to DM symptoms ([@B6]). Deregulation of the alternative splicing of the insulin receptor (*INSR*), muscle chloride channel (*CLCN1*), and dystrophin (*DMD*) mRNAs is associated with the insulin resistance ([@B7], [@B8]), myotonia ([@B9]--[@B11]), and dystrophic process ([@B12]), respectively, while missplicing of amphiphysin 2 (*BIN1*), ryanodine receptor 1 (*RYR1*), sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase SERCA1 (*ATP2A1*), and muscle calcium channel CaV1.1 (*CACNA1S*) may contribute to the skeletal muscle weakness observable in DM1 ([@B13]--[@B16]).

Cardiac defects affect 80% of individuals with DM1 and represent the second most common cause of death ([@B17], [@B18]). Initially, cardiac involvement manifests as asymptomatic electrocardiographic (ECG) abnormalities, commonly prolongation of the PR interval and QRS duration. In DM2, the frequency and severity of conduction disorders appear to be milder than in DM1 patients; however, in this patient population, a careful cardiac follow-up evaluation is also recommended ([@B19]). The most common cardiac manifestations in DM patients include dilated cardiomyopathy ventricular tachycardia and ventricular fibrillation ([@B19]--[@B22]). Sudden death is considered the result of atrioventricular block or ventricular arrhythmias ([@B23], [@B24]). To date, the molecular mechanisms responsible for cardiac defects in DM are still unclear. However, it has been reported that alteration of the alternative splicing of the cardiac isoform of troponin T (*TNNT2*) and of the cardiac sodium channel (*SCN5A*) might contribute to the reduced myocardial function and conduction abnormalities seen in DM patients ([@B25], [@B26]). *TNNT2* is a gene expressed in embryonic and adult cardiac muscle, and in embryonic skeletal muscle ([@B27]). Regulation of alternative splicing of exon 5 leads to exon inclusion in mRNAs produced during early development of heart and skeletal muscle and to exon exclusion in adult heart ([@B28]). These two *TNNT2* isoforms confer different calcium sensitivity to the myofilament, affecting the contractile properties of maturing muscle ([@B29], [@B30]). Adult cardiac muscle of DM patients shows alteration of *TNNT2* alternative splicing such that inclusion of exon 5 is inappropriately increased; thus, the expression of this fetal isoform in DM1 patients\' heart might contribute to the reduced myocardial function and conduction abnormalities seen in these patients ([@B25]).

During skeletal muscle regeneration, newly formed multinucleated myotubes express developmental markers, such as fetal isoforms of MyHC and cardiac-specific markers such as cTnT, which is also expressed in embryonic skeletal muscle ([@B31]). It has been reported that *TNNT2* is re-expressed in diseased skeletal muscle from DM patients and from patients with other neuromuscular diseases such as inclusion body myositis (IBM) ([@B32]--[@B35]). More recently, it has been observed that *TNNT2* is expressed at the mRNA level also in healthy adult skeletal muscle and that, in DM skeletal muscle, an aberrant alternative splicing pattern as in cardiac tissue is observable ([@B25], [@B34], [@B36], [@B37]). Thus, our objectives were to identify the biological role of *TNNT2* expression in DM skeletal muscles and to clarify if the expression of the aberrant fetal isoform could be secondary to myopathic changes or if it could reflect the cardiac phenotype of these patients, thus representing a muscular biomarker of cardiac involvement.

Materials and Methods {#s2}
=====================

The ethical committee Ospedale San Raffaele (Milan, Italy) reviewed and approved this study protocol, which was conducted according to the principles expressed in the Declaration of Helsinki, the institutional regulation, and Italian laws and guidelines. All patients enrolled gave a written informed consent for all blood samples and muscle biopsies used in this study.

Patients
--------

The study was performed on a total of 24 DM1 and 9 DM2 patients. The diagnosis of DM was based upon the clinical diagnostic criteria set by the International Consortium for Myotonic Dystrophy ([@B38]). Fluorescence *in situ* hybridization using a (CAGG)~5~ probe was performed on muscle frozen sections for DM2 diagnosis to verify the presence of nuclear accumulation of mutant RNA ([@B39]). DM1 genotyping was performed on genomic DNA obtained from peripheral blood leukocytes according to Valaperta et al. ([@B40]). Ten age-matched subjects with no sign of neuromuscular or cardiovascular disease were used as controls (CTR). As internal controls, two patients affected by inclusion body myositis (noDM-IBM) were also included in the study.

Neurological and Cardiac Evaluation
-----------------------------------

At the time of muscle biopsy, all DM and control subjects underwent complete clinical neurological and cardiac evaluation. Five-point MRC scale (Medical Research Council) for a total maximum score of 130 was used to evaluate muscle strength. Stage of DM1 disease was determined using the Muscular Impairment Rating Scale (MIRS) ([@B41]). Cardiac evaluation included standard 12-lead ECG, 24-h Holter monitoring and 2D-echocardiography. Patients were identified as having cardiac involvement (CI) when presented at least one ECG abnormality (PR interval ≥ 200 ms; QRS duration ≥ 100 ms; QTc \> 430 ms in female or \>450 ms in male) or left ventricular EF \< 50%. Left ventricular hypertrophy (LVH) and dilation (LVD) with rare overt systolic and diastolic dysfunction were also considered since they are relatively frequent findings on echocardiography in DM patients.

Muscle Biopsies
---------------

Biceps brachii (BB) and tibialis anterior (TA) muscle biopsies were taken under sterile conditions from a total of 24 DM1 (12 BB, 12 TA) and 9 DM2 (9 BB) patients enrolled in "The Italian Registry for Myotonic Dystrophy Type 1 and Type 2." In DM1, both BB and TA muscle biopsies were obtained for research intents, while in DM2 patients, BB biopsies were performed for diagnostic purposes. Muscle biopsies from 10 age-matched healthy subjects (6 BB, 4 TA) were used as CTR. Biopsies of vastus lateralis muscle (VL) were taken from noDM-IBM patients. All patients underwent overnight fasting before blood and muscle sample collection. Muscle tissue was flash frozen in isopentane cooled in liquid nitrogen. Routine histological or histochemical stainings were performed on serial sections (8 μm) for histopathological analysis.

Immunohistochemistry
--------------------

Serial sections (6 μm) were air-dried and rehydrated in phosphate buffer solution pH 7.4 (PBS). Sections were incubated with normal goat serum (NGS; Dako, Glostrup, Denmark) at a dilution 1:20 in PBS containing 2% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA) for 20 min at room temperature (RT) to block the non-specific binding sites. Mouse monoclonal primary antibodies against four different myosin heavy chains (MHCs) were applied to sections overnight at 4°C: MHC-fast (MHCf, 1:400 in PBS+2%BSA, Sigma-Aldrich), MHC-slow (MHCs, 1:400 in PBS+2%BSA, Sigma-Aldrich), MHC-neonatal (MHC-neo, 1:10 in PBS+2%BSA, Novocastra), and MHC-embryonal (MHC-emb, 1:20 in PBS+2%BSA, Novocastra). After washing in PBS (3 × 5 min), sections were incubated with goat anti-mouse biotinylated secondary antibody diluted 1:300 in PBS+2%BSA for 1 h. After washing in PBS (3 × 5 min), sections were incubated for 30 min with Vectastain ABC complex (Vector Laboratories, Burlingame, CA, USA) and then with 3,3′-diaminobenzidine (DAB) and hydrogen peroxide for 20 min. Mayer\'s hematoxylin was used for nuclear counterstain.

Skeletal Muscle Morphometry and Histopathological Grading
---------------------------------------------------------

To evaluate skeletal muscle damage, four histopathological parameters characteristic of DM skeletal muscle were taken into account: percentage of centrally nucleated fibers (CNF), number of nuclear clumps, atrophy (AF), and hypertrophy (HF) factors. The percentage of MHC-emb or MHC-neo positive fibers was also taken into account as parameters of muscle regeneration. The percentage of CNF and the number of nuclear clumps were evaluated on hematoxylin and eosin-stained sections. The percentage of CNF was calculated as the number of CNF divided by the total number of fibers in 10 randomly selected fields at a light microscope (magnification 200×). The number of nuclear clumps was evaluated in 10 randomly selected fields at a light microscope (magnification 200×) and the number of nuclear clumps per field was calculated. Measurement of fiber diameter and evaluation of AF and HF were made as previously described by Vihola et al. ([@B42]) using Image J (Scion Co.) on images taken on MHCf and MHCs immunostained sections (original magnification 200×). Percentage of embryonal or neonatal positive fibers and positive nuclear clump fibers was evaluated on MHC-neo immunostained sections as number of positive fibers divided by the total number of fibers in 10 randomly selected fields at a light microscope (magnification 200×). Limited to DM and CTR skeletal muscle, a grade of histopathological alteration was evaluated for each biopsy calculating the total score as the sum of the scores for several histopathological parameters. The histopathological score was assigned to each parameter according to the degree of changes observed. For the percentage of CNF: 0 = no CNF; 1 = 0 \< %CNF ≤ 10; 2 = 10 \< %CNF ≤ 15; 3 = %CNF \> 15. For the number of nuclear clumps/field: 0 = no nuclear clumps; 1 = 0 \< nuclear clumps ≤ 1; 2 = 1 \< nuclear clumps ≤ 3; 3 = nuclear clumps \> 3. For AF or HF: 0 = no fiber size variability; 1 = 1 \< Factor ≤ 2; 2 = 2 \< Factor ≤ 5; 3 = Factor \> 5. Due to the low number of MHC-emb positive fibers, only two scores were assigned to this parameter: 0 = no MHC-emb positive fibers; 1 = presence of MHC-emb positive fibers. For the percentage of MHC-neo positive fibers: 0 = no MHC-neo positive fibers; 1 = 0 \< %MHC-neo fibers ≤ 1; 2 = 1 \< %MHC-neo fibers ≤ 5; 3 = %MHC-neo fibers \> 5. Since the most affected muscles showed an evident increase of the connective tissue, for the histopathological score, this parameter was also included: 0 = no increase; 1 = increase.

RNA Extraction and cDNA Synthesis
---------------------------------

Total RNA was extracted from BB and TA biopsies using TRIzol reagent (Invitrogen, Milan, Italy). NanoPhotometer NP80 (Implen) was used to verify RNA quantity and quality. An equal amount of RNA for each sample was retrotranscribed in complementary DNA by the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Monza, Italy) according to the manufacturer\'s protocol. The resulting cDNAs were used to perform both quantitative real time-PCR and classical PCR.

Quantitative Real-Time PCR
--------------------------

The expression level of the *TNNT2* gene was measured by quantitative RT-PCR (qRT-PCR) using StepOne Plus Real-Time PCR System (Applied Biosystems) and TaqMan Gene Expression Mastermix. Commercially available TaqMan Gene Expression Assays labeled with FAM dye were used and data were normalized to GAPDH housekeeping gene expression (human TNNT2 Hs00943911_m1; human GAPDH Hs02758991_g1, Applied Biosystems). Each PCR reaction was performed in triplicate and relative gene expression was quantified using the DCt method, normalizing data to the expression of the *GAPDH* gene.

Alternative Splicing Analysis
-----------------------------

PCR for the splicing analysis of the *TNNT2* (cardiac Troponin T), *SERCA1* (Sarcoplasmic/endoplasmic reticulum calcium ATPase 1), *TNNT3* (Troponin T3, Fast Skeletal Type), *DMD* (Dystrophin), and *CLCN1* (skeletal muscle chloride channel voltage-sensitive 1) was performed using Platinum Taq Polymerase (Invitrogen, Carlsbad, CA, USA) according to manufacturer instructions. Classical PCR for splicing analysis for *NFIX* (Nuclear Factor I X), *BIN1* (Amphiphysin 2), *RYR*1 (Ryanodine Receptor 1), *CACNA1S* (Voltage-dependent L-type calcium channel subunit alpha-1S), and *LDB3* (LIM Domani Binding 3) was performed using My Taq Red Mix (Bioline), according to the manufacturer\'s protocol. For each gene, the primers used for all PCR reactions with their respective temperatures of melting (*T*~m~) and relative spliced exons analyzed are listed in [Table 1](#T1){ref-type="table"}.

###### 

List of PCR primers used for splicing analysis for each gene with the relative spliced exon.

  **Gene**   **Exon**   **Forward primer**               **Reverse primer**               ***T*~**m**~ (**°**C)[^**a**^](#TN1){ref-type="table-fn"}**
  ---------- ---------- -------------------------------- -------------------------------- -------------------------------------------------------------
  TNNT2      5          5′-ATAGAAGAGGTGGTGGAAGAGTAC-3′   5′-GTCTCAGCCTCTGCTTCAGCATCC-3′   58
  LDB3       11         5′-GACTACCAGGAACGCTTCAACC-3′     5′-GACAGAAGGCCGGATGCTG-3′        62
  NFIX       7          5′-GAGCCCTGTTGATGACGTGTTCTA-3′   5′-CTGCACAAACTCCTTCAGTGAGTC-3′   62
  SERCA1     22         5′-ATCTTCAAGCTCCGGGCCCT-3′       5′-CAGCTCTGCCTGAAGATGTG-3′       62
  TNNT3      F          5′- TTCACCATGTCTGACGAGGAAG-3′    5′- CTTCTGGGATCTTAGGAGCAGTG-3′   50
  DMD1       78         5′-TTAGAGGAGGTGATGGAGCA-3′       5′-GATACTAAGGACTCCATCGC-3        58
  CACNA1S    29         5′-GCTACTTTGGAGACCCCTGGAA-3′     5′-AGGAGGGTTCGCACTCCTTCTG-3′     60
  BIN1       11         5′-AGAACCTCAATGATGTGCTGG-3′      5′-TCGTGGTTGACTCTGATCTCGG-3′     58
  RYR1       70         5′-GACAACAAAAGCAAAATGGC-3′       5′-CTTGGTGCGTTCCTGGTCCG-3′       60
  CLCN1      7a         5′-GGTTGTCCTGAAGGAATACCTCAC-3′   5′-TCCTCTCCAGTAGTTCCGAACAG-3′    60
  GAPDH                 5′-AGCCTCCCGCTTCGCTCTCT-3′       5′-GCCAGCATCGCCCCACTTGA-3′       60

*T~m~, melting temperature*.

Total PCR products were electrophoretically resolved on 2% agarose gel for *CACNA1S, NFIX, LDB3*, and *DMD* genes; metaphor agarose gel for *TNNT2, SERCA1, TNNT3, RYR1*, and *BIN1* genes; and 6% acrylamide gel for the *CLCN1* gene. Qualitative analysis of the amplified products was performed using EtBr-stained gels (Sigma-Aldrich) scanned on a ChemiDoc Universal Hood (Biorad). ImageJ software was used to quantify the intensity of each band and the fraction of abnormally spliced isoform respect to the total amount of isoforms was calculated. The expression level of GAPDH was used as the housekeeping gene. Each PCR was performed on cDNA samples derived from two independent retrotranscriptions.

Protein Extraction and Western Blot Analysis
--------------------------------------------

To analyze protein expression of cardiac troponin T (cTnT), skeletal muscle biopsies were homogenized in 60 μl of 50 mM Tris--HCl with 5% SDS (pH 7.5) to obtain whole-cell protein extracts. Samples were incubated on ice for 15 min and then centrifuged at 5,700 × *g* for 15 min at 4°C, and the supernatant was collected and stored at −80°C. As positive control, whole protein extract from human heart auricula was also obtained.

Protein concentration was determined using Pierce BCA Assay Kit (Thermo Scientific, Rockford, USA) and 25 μg of proteins was separated by SDS-PAGE and transferred to nitrocellulose membranes. Non-specific binding was blocked with Tris--HCl buffer, pH 7.5 (TBS), containing 5% BSA and then membranes were incubated with primary antibodies: mouse monoclonal anti-cTnT (clone 1C11, Abcam, 1:2,000) and mouse monoclonal anti-αTubulin (clone B-5-1-2, Sigma-Aldrich, 1:1,000) used as an internal loading control. After washing with TBS + 0.3% Tween20, membranes were incubated with HRP-conjugated anti-mouse antibody (Jackson ImmunoResearch Laboratories, Inc.) diluted 1:5,000 in TBS + 5%BSA + 0.2% Tween 20. Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific, Meridian Rd., Rockford, USA) was used for immunodetection.

Statistical Analysis
--------------------

Categorical variables are presented as proportions, and continuous variables are presented as mean (± SD) and median \[interquartile range\].

For evaluation of differences in qRT-PCR and alternative splicing analysis between CTR and DM1 or DM2 patients, nonparametric, Kruskal--Wallis test was used. Dwass, Steel, Critchlow--Fligner multiple comparison procedure was used to compare levels where Kruskal--Wallis test was statistically significant. Correlation analysis was performed using nonparametric Spearman Rho. All *p*-values are two-tailed and considered significant if *p* \< 0.05. Statistical analysis was performed using SAS software, version 9.4 (SAS Institute, Inc., Cary, NC).

Results {#s3}
=======

Patients
--------

This study was performed on a total of 24 DM1 and 9 DM2 patients compared to 12 control subjects. The DM1 cohort was represented by patients affected by the mild form (range of CTG repeat expansion E1 = 50--149) or by the classical adult form of the disease (range of CTG repeat expansion E2 = 150--1,000); the DM2 cohort was represented by patients with classical Proximal Myotonic Myopathy (PROMM) phenotype. DM patients were divided into two subgroups based on the presence (CI) or not (NCI) of cardiac involvement. Among DM1, 10 patients were classified as NCI while 14 were classified as CI. Among DM2, five patients were classified as NCI while four were classified as CI. At echocardiogram, LVH was observed in two DM patients (DM1-7 CI and DM2-9 CI) who also were pacemaker carriers. No patients presented LVD and systolic or diastolic dysfunctions except for DM1-7 CI who showed diffuse left ventricular hypokinesis. All patients were ambulant and mildly--moderately affected ([Table 2](#T2){ref-type="table"}). As internal controls, two patients affected by inclusion body myositis (noDM-IBM) were used. Clinical data and skeletal muscle biopsy were collected during patient hospitalization. Clinical data on DM and control patients are reported in [Table 2](#T2){ref-type="table"}.

###### 

Clinical data on control, DM1, and DM2 patients.

                    **Gender**   **Age at biopsy**   **Age at onset**   **CTG repeat size**   **MRC[^**a**^](#TN2){ref-type="table-fn"}**   **MIRS[^**b**^](#TN3){ref-type="table-fn"}**   **PR interval[^**c**^](#TN4){ref-type="table-fn"}**   **QRS duration[^**d**^](#TN5){ref-type="table-fn"}**   **QTc[^**e**^](#TN6){ref-type="table-fn"}**   **%EF[^**f**^](#TN7){ref-type="table-fn"}**   **Drugs[^**g**^](#TN8){ref-type="table-fn"}**
  ----------------- ------------ ------------------- ------------------ --------------------- --------------------------------------------- ---------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ --------------------------------------------- --------------------------------------------- -----------------------------------------------
  CTR1 (BB)         F            42                  --                 --                    --                                            --                                             168                                                   90                                                     403                                           66                                            None
  CTR2 (BB)         F            50                  --                 --                    --                                            --                                             157                                                   84                                                     410                                           68                                            None
  CTR3 (BB)         F            44                  --                 --                    --                                            --                                             184                                                   79                                                     415                                           63                                            None
  CTR4 (BB)         F            52                  --                 --                    --                                            --                                             173                                                   82                                                     404                                           65                                            None
  CTR5 (BB)         M            44                  --                 --                    --                                            --                                             165                                                   77                                                     412                                           65                                            None
  CTR6 (BB)         F            47                  --                 --                    --                                            --                                             176                                                   92                                                     417                                           69                                            Levothyroxine
  CTR7 (TA)         M            26                  --                 --                    --                                            --                                             168                                                   94                                                     404                                           65                                            None
  CTR8 (TA)         F            29                  --                 --                    --                                            --                                             159                                                   92                                                     410                                           68                                            None
  CTR9 (TA)         M            24                  --                 --                    --                                            --                                             165                                                   84                                                     408                                           62                                            None
  CTR10 (TA)        F            27                  --                 --                    --                                            --                                             172                                                   79                                                     412                                           65                                            None
  DM1-1 NCI (BB)    F            45                  35                 460                   103                                           4                                              160                                                   95                                                     420                                           72                                            Levothyroxine
  DM1-2 NCI (BB)    M            66                  50                 100                   130                                           1                                              184                                                   88                                                     396                                           68                                            None
  DM1-3 NCI (BB)    M            42                  36                 390                   128                                           2                                              172                                                   82                                                     428                                           64                                            None
  DM1-4 NCI (BB)    F            48                  30                 240                   105                                           4                                              168                                                   82                                                     422                                           79                                            None
  DM1-5 CI (BB)     M            42                  10                 950                   105                                           4                                              202                                                   124                                                    429                                           58                                            None
  DM1-6 CI (BB)     F            65                  15                 300                   117                                           3                                              156                                                   204                                                    520                                           65                                            ASA, Acarbose, Levothyroxine, Metformin
  DM1-7 CI (BB)     M            43                  18                 500                   119                                           3                                              Pacemaker carrier                                     Enalapril, ASA                                                                                                                                     
  DM1-8 CI (BB)     M            43                  33                 240                   111                                           3                                              214                                                   126                                                    403                                           66                                            None
  DM1-9 CI (BB)     F            45                  40                 300                   127                                           3                                              216                                                   116                                                    440                                           68                                            Flecainide
  DM1-10 CI (BB)    M            50                  28                 220                   113                                           4                                              202                                                   110                                                    425                                           65                                            None
  DM1-11 CI (BB)    M            39                  37                 890                   118                                           3                                              210                                                   107                                                    434                                           63                                            None
  DM1-12 CI (BB)    F            56                  31                 490                   118                                           3                                              218                                                   112                                                    412                                           65                                            Levothyroxine, Enalapril, ASA
  DM2-1 NCI (BB)    F            50                  39                 --                    125                                           --                                             124                                                   86                                                     422                                           64                                            None
  DM2-2 NCI (BB)    M            61                  55                 --                    118                                           --                                             182                                                   82                                                     405                                           72                                            ASA, Metformin
  DM2-3 NCI (BB)    M            59                  65                 --                    124                                           --                                             160                                                   72                                                     386                                           66                                            ASA, Levothyroxine, Metformin
  DM2-4 NCI (BB)    F            51                  45                 --                    129                                           --                                             164                                                   79                                                     425                                           62                                            None
  DM2-5 NCI (BB)    F            56                  31                 --                    123                                           --                                             156                                                   87                                                     423                                           60                                            ASA, Metformin, Insulin, Simvastatin
  DM2-6 CI (BB)     F            48                  53                 --                    124                                           --                                             220                                                   70                                                     424                                           60                                            None
  DM2-7 CI (BB)     M            64                  57                 --                    129                                           --                                             226                                                   114                                                    417                                           71                                            ASA
  DM2-8 CI (BB)     M            56                  50                 --                    126                                           --                                             164                                                   110                                                    432                                           66                                            Warfarin
  DM2-9 CI (BB)     M            61                  27                 --                    118                                           --                                             Pacemaker carrier                                     Mexiletine, Simvastatin                                                                                                                            
  DM1-13 NCI (TA)   F            31                  31                 560                   128                                           1                                              152                                                   80                                                     379                                           67                                            None
  DM1-14 NCI (TA)   F            29                  18                 490                   126                                           2                                              144                                                   84                                                     402                                           56                                            Mexiletine
  DM1-15 NCI (TA)   F            34                  Unknown            255                   126                                           3                                              174                                                   86                                                     402                                           64                                            None
  DM1-16 NCI (TA)   F            22                  20                 \>800                 129                                           2                                              142                                                   96                                                     420                                           72                                            None
  DM1-17 NCI (TA)   M            29                  14                 \>800                 129                                           3                                              167                                                   89                                                     411                                           65                                            None
  DM1-18 NCI (TA)   M            35                  14                 680                   112                                           3                                              194                                                   99                                                     417                                           68                                            Mexiletine
  DM1-19 CI (TA)    F            44                  35                 360                   125                                           3                                              248                                                   109                                                    409                                           56                                            Levothyroxine
  DM1-20 CI (TA)    F            22                  2                  455                   113                                           4                                              232                                                   109                                                    419                                           62                                            None
  DM1-21 CI (TA)    F            42                  16                 290                   119                                           3                                              262                                                   142                                                    446                                           65                                            None
  DM1-22 CI (TA)    F            39                  33                 \>800                 125                                           4                                              202                                                   130                                                    420                                           54                                            Mexiletine
  DM1-23 CI (TA)    F            30                  11                 \>800                 114                                           3                                              168                                                   164                                                    460                                           64                                            Modafinil
  DM1-24 CI (TA)    M            33                  21                 220                   130                                           2                                              216                                                   107                                                    436                                           60                                            Mexiletine
  noDM-IBM1 (VL)    F            68                  --                 --                    122                                                                                          153                                                   86                                                     402                                           65                                            Atenolol
  noDM-IBM2 (VL)    F            63                  --                 --                    130                                                                                          165                                                   82                                                     402                                           66                                            Metformin

BB, biceps brachii; TA, tibialis anterior; VL, vastus lateralis; F, female; M, male.

Medical Research Council, scale for muscle strength; scale (0--5 grade) on 13 muscles at both sides in the upper and lower limbs for a total of 130 maximum score.

Muscle Impairment Rating Scale, stage of the disease for myotonic dystrophy type 1 (DM1) patients ([@B41]).

PR interval normal value \<200 ms.

QRS duration normal value \<100 ms.

QTc normal values ≤430 ms in female or ≤450 ms in male.

Left ventricular ejection fraction normal value \>50%.

Therapeutic treatment at the time of muscle biopsy.

Muscle Histopathology and Immunohistochemistry
----------------------------------------------

The results of the quantitative analysis of histopathological parameters of routine stained sections and of immunostained sections are reported in [Table 3](#T3){ref-type="table"}. Histological and immunohistochemical stainings revealed no myopathic changes in skeletal muscle biopsies from CTR. Routine stainings performed on muscle BB and TA transverse sections revealed the presence of the histological alterations commonly observable in DM skeletal muscle such as nuclear clump fibers, nuclear centralization, fiber size variability, and fibrosis ([Figure 1](#F1){ref-type="fig"}). When considering the histopathological analysis, in BB muscle biopsies, a clear increase in percentage of CNF and in the number of nuclear clumps was present in both DM1 and DM2 patients compared to CTR. The percentage of CNF was significantly higher in DM1-CI and in DM2-CI compared to CTR muscles, whereas the number of nuclear clumps appeared to be significantly higher in DM1-CI and in DM2-NCI compared to CTR muscles. A high number of nuclear clumps was evident also in DM2-CI even if not significantly different from CTR due to the high interindividual variability. In TA muscles, the percentage of CNF was significantly higher in DM1-CI compared to CTR. No significant differences in the number of nuclear clumps were found between DM1-CI and DM1-NCI compared to CTR. The immunohistochemical staining of MHC-slow and MHC-fast myosin allowed better evaluation of type 1 and type 2 fiber atrophy (AF) and hypertrophy (HF) factors. In DM1 BB, the AF was significantly higher in DM1-CI compared to CTR, while no differences were found in HF. No significant differences were found in AF and HF between DM1 TA or DM2 and the corresponding CTR groups. The immunostaining of two fetal isoforms of myosin showed that in DM1 and DM2 patients, only very few atrophic fibers in the most severely affected muscles expressed MHC-emb and no nuclear clumps were positive for this myosin isoform. Indeed, no significant differences were observed in the percentage of MHC-emb fibers in both DM1 (BB and TA) and DM2 muscles compared to CTR. The expression of MHC-neo was present in highly atrophic fibers and in almost all nuclear clumps of DM1 and DM2 muscle. In BB muscles, the percentage of MHC-neo fibers appear to be significantly higher in DM2-NCI compared to CTR, while in TA muscles, this parameter was significantly higher in DM1-CI compared to CTR. To evaluate the global degree of myopathic changes observed by microscopic analysis, a histopathological score was assigned to each DM biopsy. The results of this evaluation showed that among the BB muscles, the histopathological score was higher in both DM1 and DM2 with significant differences in DM1-CI and in the two DM2 subgroups compared to CTR. In TA, both DM1 subgroups showed a score higher than that observed in CTR, but reaching statistical significance only in DM1-CI. As expected, in DM1 patients, the histopathological score appeared to be higher in TA than in BB muscles even if with a difference that is not statistically significant. No statistically significant differences were found between the CI and NCI subgroups in both DM1 and DM2 muscles in any of the parameters considered. In noDM-IBM patients, routine staining showed a fiber size variability due to the presence of atrophic fibers and endomysial inflammatory infiltrations ([Figures 1U--Z](#F1){ref-type="fig"}). The immunohistochemical staining revealed an increase of the atrophy factor and of the percentage of MHC-emb fibers compared to CTR muscles. Moreover, a clear increase in the percentage of MHC-neo fibers was also observed compared to CTR and DM skeletal muscles.

###### 

Quantitative analysis of histopathological parameters and muscle pathology score.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                           **CTR**\                                           **DM1-NCI**\           **DM1-CI**\                                          **KW**\   **DM2-NCI**\                                       **DM2-CI**\                                        **KW**\   **CTR**\              **DM1-NCI**\                                     **DM1-CI**\                                        **KW**\   **noDM-IBM**\
                           **(BB = 6)[^**a**^](#TN9){ref-type="table-fn"}**   **(BB = 4)**           **(BB = 8)**                                         ***p***   **(BB = 5)**                                       **(BB = 4)**                                       ***p***   **(TA = 4)**          **(TA = 6)**                                     **(TA = 6)**                                       ***p***   **(VL = 2)**
  ------------------------ -------------------------------------------------- ---------------------- ---------------------------------------------------- --------- -------------------------------------------------- -------------------------------------------------- --------- --------------------- ------------------------------------------------ -------------------------------------------------- --------- ---------------
  \% CNF                   1.21 ± 1.66\                                       7.59 ± 10.39\          19.47 ± 18.75[^\*\*^](#TN11){ref-type="table-fn"}\   0.014     10.61 ± 7.10\                                      26.42 ± 7.73[^\*^](#TN10){ref-type="table-fn"}\    0.008     ± 0.00\               18.47 ± 14.73\                                   50.03 ± 39.35[^\*^](#TN10){ref-type="table-fn"}\   0.016     0.87 ± 0.87
                           0.75 \[0.00--1.27\]                                4.02 \[0.28--14.91\]   12.55 \[9.43--21.04\]                                          9.73 \[9.02--13.08\]                               25.25 \[20.01--32.82\]                                       0.00 \[0.00--0.00\]   18.84 \[6.43--28.83\]                            41.18 \[26.30--88.30\]                                       

  Nuclear clumps/field     ± 0.00\                                            0.50 ± 0.59\           1.55 ± 1.15[^\*\*^](#TN11){ref-type="table-fn"}\     0.004     1.30 ± 0.72[^\*\*^](#TN11){ref-type="table-fn"}\   1.55 ± 2.23[^\*\*^](#TN11){ref-type="table-fn"}\   0.007     ± 0.00\               0.61 ± 0.90\                                     1.25 ± 2.63\                                       0.301     0.00 ± 0.00
                           0.00 \[0.00--0.00\]                                0.35 \[0.05--0.95\]    1.25 \[0.85--2.05\]                                            1.00 \[0.90--1.90\]                                0.45 \[0.40--2.70\]                                          0.00 \[0.00--0.00\]   0.10 \[0.00--1.33\]                              0.24 \[0.00--0.43\]                                          

  AF                       0.83 ± 0.27\                                       3.17 ± 3.78\           3.52 ± 2.10\                                         0.055     3.00 ± 2.47\                                       1.96 ± 1.53\                                       0.143     0.29 ± 0.09\          2.72 ± 3.32\                                     2.86 ± 2.16\                                       0.289     5.44 ± 1.93
                           0.83 \[0.67--0.94\]                                1.56 \[1.06--5.28\]    3.07 \[2.47--5.11\]                                            1.97 \[1.57--4.06\]                                1.45 \[0.91--3.01\]                                          0.31 \[0.22--0.37\]   1.38 \[0.18--5.06\]                              2.75 \[1.17--5.07\]                                          

  HF                       0.68 ± 0.23\                                       1.79 ± 2.54\           0.77 ± 0.50\                                         0.989     1.08 ± 1.01\                                       2.38 ± 0.93\                                       0.072     2.01 ± 1.05\          1.80 ± 1.60\                                     ± 4.51\                                            0.147     0.28 ± 0.28
                           0.64 \[0.59--0.85\]                                0.74 \[0.25--3.34\]    0.65 \[0.35--1.22\]                                            0.79 \[0.36--1.46\]                                2.16 \[1.68--3.09\]                                          1.91 \[1.12--2.90\]   1.55 \[0.56--2.05\]                              6.37 \[1.36--7.34\]                                          

  \% MHC-emb fibers        0.08 ± 0.19\                                       ± 0.00\                0.27 ± 0.31\                                         0.173     0.57 ± 0.55\                                       ± 0.00\                                            0.100     ± 0.00\               0.89 ± 1.13\                                     1.39 ± 1.07\                                       0.082     7.62 ± 4.81
                           0.00 \[0.00--0.00\]                                0.00 \[0.00--0.00\]    0.19 \[0.00--0.50\]                                            0.70 \[0.00--0.73\]                                0.00 \[0.00--0.00\]                                          0.00 \[0.00--0.00\]   0.54 \[0.00--1.52\]                              1.19 \[0.69--2.52\]                                          

  \% MHC-neo fibers        0.44 ± 0.66\                                       0.43 ± 0.61\           2.20 ± 2.30\                                         0.086     3.56 ± 2.69[^\*^](#TN10){ref-type="table-fn"}\     1.40 ± 0.91\                                       0.012     ± 0.00\               2.79 ± 2.68\                                     5.65 ± 5.57[^\*^](#TN10){ref-type="table-fn"}\     0.027     40.07 ± 4.05
                           0.00 \[0.00--0.72\]                                0.21 \[0.00--0.85\]    1.43 \[0.71--3.25\]                                            2.43 \[2.01--3.61\]                                1.07 \[0.80--2.01\]                                          0.00 \[0.00--0.00\]   2.16 \[0.00--5.56\]                              4.04 \[1.11--8.86\]                                          

  Muscle pathology score   ± 0.89\                                            5.55 ± 3.11\           8.12 ± 2.47[^\*\*^](#TN11){ref-type="table-fn"}\     0.003     7.20 ± 1.64[^\*^](#TN10){ref-type="table-fn"}\     8.50 ± 1.19[^\*^](#TN10){ref-type="table-fn"}\     0.004     1.50 ± 0.58\          7.50 ± 4.76[^\*^](#TN10){ref-type="table-fn"}\   11.00 ± 2.83[^\*^](#TN10){ref-type="table-fn"}\    0.015     /
                           1.00 \[0.00--2.00\]                                6.50 \[3.50--7.50\]    9.00 \[7.50--9.00\]                                            7.00 \[6.00--7.00\]                                7.50 \[7.00--10.00\]                                         1.50 \[1.00--2.00\]   7.50 \[3.00--12.00\]                             12.00 \[8.00--13.00\]                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are mean (± SD)/median \[Q1--Q3\].

Number of muscles analyzed.

%CNF, percent of central nuclear fiber; AF, atrophy factor; HF, hypertrophy factor; KW, Kruskal--Wallis test; BB, biceps brachii: TA, tibialis anterior; VL, vastus lateralis.

p \< 0.05,

*p \< 0.01 Dwass, Steel, Critchlow--Fligner multiple post-hoc comparison procedure: patient group vs. CTR group*.

![Hematoxylin and eosin (HE) staining and immunostaining of fast myosin heavy chain (MHC-fast) and neonatal myosin heavy chain (MHC-neo) of representative DM1 **(A--F)** and DM2 **(G--N)** biceps brachii (BB), DM1 tibialis anterior (TA) **(O--T)**, and noDM-IBM **(U--Z)** vastus lateralis (VL). DM1 and DM2 patient groups have been divided into two subgroups according to the presence of cardiac abnormalities: NCI, no cardiac involvement; CI, cardiac involvement. Patient group and investigated proteins are indicated. Both DM1 and DM2 show a high fiber size variability **(A,D,G,L,O,R)**. In DM1 atrophic fibers (black arrow) and nuclear clumps (black arrowhead) are both fast (brown fibers) or slow fibers (unstained fibers) **(B,E,P,S)** while in DM2, essentially all atrophic fibers (black arrow) and nuclear clumps (black arrowhead) are identified as fast fibers (brown fibers; **H,M**). Only few atrophic fibers (brown fibers) and almost all nuclear clumps (white arrow) express MyHC-neo **(C,F,I,N,Q,T)**. In the noDM-IBM patient, skeletal muscle shows the presence of numerous atrophic fibers, both fast and slow myosin positive, and several inflammatory infiltrates (white arrowhead) **(U,V)**. Numerous MHC-neo positive fibers are present **(Z)**. Original magnification 200×.](fneur-10-00992-g0001){#F1}

*TNNT2* Expression and Alternative Splicing
-------------------------------------------

Total *TNNT2* mRNA expression was analyzed in both control and DM muscle biopsies by qRT-PCR ([Figures 2A--C](#F2){ref-type="fig"}). *TNNT2* expressed both in BB and in TA obtained from CTR patients. When considering BB muscles, a slight increase in mRNA expression was present in DM1 and DM2 patients even if it is not significantly different from CTR. The higher levels of *TNNT2* were observed in DM1-CI but without statistical differences compared to CTR BB. In DM1-NCI and DM2 patients, *TNNT2* expression appeared to be similar to that observed in CTR BB muscles ([Figure 2A](#F2){ref-type="fig"}). In TA muscles, *TNNT2* expression was statistically higher in DM1 compared to CTR TA (Mann--Whitney, *p* = 0.01). When considering the two subgroups, *TNNT2* was higher in both DM1-NCI and DM1-CI compared to CTR subjects but with a statistically significant difference only for DM1-CI ([Figure 2B](#F2){ref-type="fig"}). In noDM-IBM, a more than 100-fold change increase in *TNNT2* expression compared to CTR BB was found ([Figure 2C](#F2){ref-type="fig"}). In order to verify if *TNNT2* mRNA was translated into protein in adult healthy and diseased skeletal muscle, cTnT protein expression was analyzed by western blot. The primary antibody detected the typical band at the molecular weight of cTnT (37 kDa) in cardiac tissue. This band was present also in diseased skeletal muscle of noDM-IBM patients but absent both in CTR healthy muscle and in diseased muscle of DM1 and DM2 patients ([Figure 2D](#F2){ref-type="fig"}). The cTnT antibody detected additional bands in all samples at molecular weights below that of cTnT; however, these bands could represent Slow or Fast skeletal TnT as identified using LC-MS/MS by Schmid et al. ([@B43]). Since our study did not focus on cTnT protein expression, we thus cannot be sure in all instances that the mRNA signals resulted in altered protein expression.

![**(A--D)** mRNA and protein *TNNT2* expression in skeletal muscle. *TNNT2* gene expression measured by qRT-PCR in biceps brachii (BB) muscle samples **(A)** and tibialis anterior (TA) muscle samples **(B)** from CTR (BB = 6; TA = 4), DM1 (BB = 12; TA = 12), and DM2 (BB = 9) patients. DM1 and DM2 patient groups have been divided into two subgroups according to the presence of cardiac abnormalities: NCI, no cardiac involvement; CI, cardiac involvement. The expression level of *TNNT2* has been quantified in skeletal muscle (vastus lateralis) of patients affected by inclusion body myositis (noDM-IBM) **(C)**. Histograms represent mean values and bars represent standard error of the mean (SEM). *GAPDH* has been chosen as the housekeeping, internal control. Each PCR reaction has been performed in triplicate. The differences between subgroups have been assessed by nonparametric, Kruskal-Wallis test. Results from Dwass, Steel, Critchlow**--**Fligner multiple *post-hoc* comparison procedure: NCI or CI subgroups vs. CTR, \**p* \< 0.05. **(D)** Representative western blot analysis of cTnT protein expression (37 kDa) in muscle biopsies obtained from CTR, noDM-IBM, DM1, and DM2 patients. Whole protein extract from human heart auricula has been used as positive control.](fneur-10-00992-g0002){#F2}

As expected, the analysis of the alternative splicing of the *TNNT2* gene showed that the fetal isoform (exon 5 including) was significantly more expressed in DM1 BB (Mann--Whitney: *p* = 0.001), DM2 BB (Mann--Whitney: *p* = 0.004), and DM1 TA (Mann--Whitney: *p* = 0.001) compared to the corresponding CTR muscles. When considering the BB and TA subgroups, both CI and NCI showed a significantly higher expression of *TNNT2* fetal isoform compared to CTR except for DM1-NCI BB, which showed a high interindividual variability ([Figures 3A--D](#F3){ref-type="fig"}). However, among all muscles analyzed, the *TNNT2* missplicing is more evident in DM1 (both BB and TA) than in DM2 muscles ([Figures 3A,C](#F3){ref-type="fig"}). Indeed, fetal isoform is more expressed (more than 50% of the total) than the adult isoform in all DM1 BB and TA muscles except for two patients (DM1-2 NCI and DM1-16 NCI) who did not present cardiac abnormalities, and their muscle tissue did not show any histopathological alterations. On the contrary, almost all DM2 muscles expressed more adult than fetal isoform ([Figure 3A](#F3){ref-type="fig"}). Among internal controls, the fetal isoform expression was slightly higher in noDM-IBM patients compared to CTR; however, the amount of fetal isoform was clearly lower than the adult one ([Figures 3E,F](#F3){ref-type="fig"}).

![**(A--F)** *TNNT2* alternative splicing in skeletal muscle. **(A,C,E)** Panels showing the reverse transcriptase-polymerase chain reaction (RT-PCR) splicing assay of the *TNNT2* gene in biceps brachii (BB) **(A)** and tibialis anterior (TA) muscle samples **(C)** from CTR, DM1, and DM2 patients. DM1 and DM2 patient groups have been divided into two subgroups according to the presence of cardiac abnormalities: NCI, no cardiac involvement; CI, cardiac involvement. *TNNT2* alternative splicing has been analyzed in vastus lateralis of patients affected by inclusion body myositis (noDM-IBM) **(E)**. The products that include the specific exon 5 (Ex) and those that exclude the specific exon 5 (Δ) have been indicated. **(B,D,F)** Analysis of the percentage of altered isoform (exon 5 including) expression of the *TNNT2* gene in BB **(B)**, TA **(D)**, and in noDM-IBM muscle samples **(F)**. Histograms represent mean values and bars represent SEM. *GAPDH* has been chosen as the housekeeping, internal control. Each PCR reaction has been performed in triplicate. The differences between subgroups have been assessed by nonparametric, Kruskal**--**Wallis test. Results from Dwass, Steel, Critchlow**--**Fligner multiple *post-hoc* comparison procedure: NCI or CI subgroups vs. CTR, \**p* \< 0.05, \*\**p* \< 0.01.](fneur-10-00992-g0003){#F3}

Skeletal Muscle-Specific Genes Alternative Splicing
---------------------------------------------------

We have analyzed the splicing isoforms of several muscle-specific genes (*BIN1, TNNT3, DMD, RYR1, SERCA1, NFIX, LDB3, CACNA1S*, and *CLCN1*) that are linked to impaired muscle functions in DM pathologies. In BB muscles, except for *BIN1* (in both DM1 and DM2 patients), *DMD1* (in DM2 patients), and *SERCA1* (in DM1 patients), a statistically significant alteration of alternative splicing of the genes examined was present in DM1 and DM2 compared to CTR muscles (data not shown). The differential abnormal splicing patterns of *TNNT3, RyR1, SERCA1, LDB3*, and *CLCN1* appeared more pronounced in DM2 BB than in DM1 BB. When considering DM1 BB, the alterations of the alternative splicing of the genes considered were more evident in DM1-CI with *TNNT3* and *CACNA1S* showing abnormal splicing with significant differences between DM1-NCI and DM1-CI ([Figures 4A,D](#F4){ref-type="fig"}). In DM2 BB, the splicing pattern was similar in DM2-NCI and DM2-CI ([Figures 4A,D](#F4){ref-type="fig"}). In TA muscles, the splicing alterations appeared to be higher in both DM1-NCI and DM1-CI compared to CTR; however, statistical analysis of the differences between DM1 and CTR groups could not be performed since only two CTR subjects were analyzed. Considering the two subgroups, the splicing alterations were slightly higher in DM1-CI but with no significant differences compared to DM1-NCI ([Figures 4B,E](#F4){ref-type="fig"}). Despite the important histopathological alterations, noDM-IBM patients showed a clearly higher expression of the fetal than adult isoform except for the *RYR*1 gene ([Figures 4C,F](#F4){ref-type="fig"}).

![**(A--C)** Alternative splicing of muscle-specific genes in skeletal muscle. Panels showing the reverse transcriptase-polymerase chain reaction (RT-PCR) splicing assay of *BIN1, TNNT3, DMD, RYR1, SERCA1, NFIX, LDB3, CACNA1S*, and *CLCN1* genes in biceps brachii (BB) **(A)** and tibialis anterior (TA) muscle samples **(B)** from CTR, DM1, and DM2 patients. DM1 and DM2 patient groups have been divided into two subgroups according to the presence of cardiac abnormalities: NCI, no cardiac involvement; CI, cardiac involvement. Alternative splicing of the muscle-specific genes has been analyzed in vastus lateralis of patients affected by inclusion body myositis (noDM-IBM) **(C)**. The products that include the specific (Ex) and those that exclude the specific exon (Δ) have been indicated. Analysis of the percentage of altered isoforms expression in BB **(D)**, TA **(E)**, and in noDM-IBM muscle samples **(F)**. Histograms represent mean values and bars represent SEM. *GAPDH* has been chosen as the housekeeping, internal control. Each PCR reaction has been performed in triplicate. The differences between subgroups have been assessed by nonparametric, Kruskal--Wallis test. Results from Dwass, Steel, Critchlow--Fligner multiple *post-hoc* comparison procedure: NCI or CI subgroups vs. CTR, \**p* \< 0.05, \*\**p* \< 0.01; NCI vs. CI, °*p* \< 0.05.](fneur-10-00992-g0004){#F4}

Correlations
------------

The total mRNA expression level of *TNNT2* was correlated with the percentage of fibers expressing MHC-neo isoform in order to verify if a regenerative process was present in the muscles examined. The correlation with the percentage of MHC-emb fibers was not considered since the number of positive fibers resulted very low in DM skeletal muscles. Total expression significantly correlated with the percentage of MHC-neo positive fibers when considering both all muscle samples examined (Spearman test: *r* = 0.45, *p* = 0.002) and also when considering only the DM muscles (Spearman test: *r* = 0.52, *p* = 0.0003). Among BB muscles, no correlation was evident in both DM1 and DM2 patients, except for DM1-CI patients (Spearman test: *r* = 0.57, *p* = 0.03). In DM1 TA muscles, the *TNNT2* expression significantly correlated with the percentage of MHC-neo positive fibers either when considering all TA muscles (Spearman test: *r* = 0.82, *p* = 0.0002) or when considering DM1-NCI (Spearman test: *r* = 0.64, *p* = 0.05) and DM1-CI (Spearman *r* = 0.84, *p* = 0.004) separately. In order to verify if the expression levels of *TNNT2* were related to DM histopathological alterations, the correlation between total mRNA expression and DM histopathological score was performed. A clear correlation was found when considering all the DM muscles examined in this study (Spearman test: *r* = 0.54, *p* = 0.0002). No correlation was present when considering DM1 BB and DM2 BB muscles separately, while a significant correlation was evident in TA muscle of DM1 patients (Spearman test: *r* = 0.83, *p* = 0.0001) and in both DM1-NCI (Spearman test: *r* = 0.77, *p* = 0.01) and DM1-CI patients (Spearman test: *r* = 0.82, *p* = 0.006).

Results regarding correlations between the total expression of *TNNT2* and patient clinical data are reported in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}. When considering all the muscles analyzed, no correlations were found between the total expression of *TNNT2* and patient age, while a significant correlation was present in DM2 and in DM1 TA. Regarding DM1 patients, cTnT expression did not correlate with age at onset, CTG repeat expansion size, or MIRS. A significant correlation was found between cTnT expression and MRC in the DM1 TA group.

Since several studies on muscular dystrophies reported that splicing changes may be a general phenomenon of muscle disease and can be secondary to muscle regeneration ([@B44], [@B45]), splicing alteration of *TNNT2* and of the muscle-specific genes analyzed was correlated to the percentage of MHC-neo fibers and to DM histopathological score. Regarding the *TNNT2* gene, splicing alteration significantly correlates with the percentage of MHC-neo fibers either when considering all the muscles analyzed (Spearman test: *r* = 0.45, *p* = 0.002) and all the DM muscles (Spearman test: *r* = 0.52, *p* = 0.0003). Among BB muscles, this correlation resulted significant in DM1 patients (Spearman test: *r* = 0.56, *p* = 0.01) and in the subgroup of DM1-CI patients (Spearman test: *r* = 0.66, *p* = 0.01), as well as in DM2 patients (Spearman test: *r* = 0.57, *p* = 0.03) and in the subgroup of DM2-NCI patients (Spearman test: *r* = 0.74, *p* = 0.01). This correlation resulted significant also in DM1 TA (Spearman test: *r* = 0.58, *p* = 0.02) and in DM1-CI TA muscles (Spearman test: *r* = 0.82, *p* = 0.007). A clear correlation was also present between the expression of the fetal *TNNT2* isoform and DM histopathological score either when considering all DM muscles (Spearman test: *r* = 0.68, *p* \< 0.0001) and DM1 BB (Spearman test: *r* = 0.80, *p* \< 0.0001), DM2 BB (Spearman test: *r* = 0.67, *p* = 0.008), and DM1 TA (Spearman test: *r* = 0.61, *p* = 0.01) muscles separately. Similar results were obtained when considering the correlation between the percentage of MHC-neo fibers or DM histopathological score and the splicing alteration of muscle-specific genes considered in this study ([Supplementary Tables 2](#SM2){ref-type="supplementary-material"}, [3](#SM3){ref-type="supplementary-material"}).

Results regarding correlations between the expression of the *TNNT2* fetal isoform and patient clinical data are reported in [Supplementary Table 4](#SM4){ref-type="supplementary-material"}. When considering all the muscles analyzed, the expression of the *TNNT2* fetal isoform did not correlate with patient age, while in the DM cohort, it significantly correlates with age at onset. In DM1 patients, no correlations were present between the expression of the fetal isoform and the CTG repeat expansion size while, limited to DM1 BB, the expression of *TNNT2* fetal isoform significantly correlated with MRC and MIRS.

In order to verify if the alteration of the *TNNT2* alternative splicing was more evident in DM patients who showed cardiac alterations, the levels of fetal *TNNT2* isoform were correlated to the cardiac parameters considered. Results are reported in [Supplementary Table 4](#SM4){ref-type="supplementary-material"}. Among the cardiac parameters considered, QRS showed a significant correlation with the expression of the fetal isoform of *TNNT2* in the DM1 cohort. Indeed, the correlation was more evident when considering all DM1 patients and in the DM1 CI subgroups both at the BB and TA level. On the contrary, no correlations were evident in DM2 patients. Nevertheless, it should be noted that the two DM patients with pacemaker (DM1-7 CI and DM2-9 CI) did not show the highest level of *TNNT2* fetal isoform ([Figure 3A](#F3){ref-type="fig"}).

Discussion {#s4}
==========

Cardiac involvement is an important cause of premature death in DM patients and one possible molecular explanation to cardiac dysfunctions is the misregulation of alternative splicing of *TNNT2* and *SCN5A* pre-mRNA in cardiac tissue ([@B25], [@B26]). Recently, several authors have reported that DM patients show elevated serum levels of cTnT, cTnI, and NT-pro-BNP, suggesting that these serum cardiac biomarkers could be used to identify DM patients at increased risk of developing myocardial conduction abnormalities and for stratification of subjects in clinical trials ([@B34], [@B43], [@B46]). However, to date, no cardiac biomarkers have been identified that may serve as an accurate biomarker of cardiac involvement that could be used in clinical trials.

It has been reported that in DM patients, the alternative splicing of the *TNNT2* gene, which encodes for the cardiac isoform of troponin T (cTnT), is disrupted in skeletal muscle as in cardiac muscle ([@B25], [@B34], [@B36], [@B37]). Thus, the aim of our study was to clarify if the expression of the *TNNT2* aberrant fetal isoform in skeletal muscle could be secondary to skeletal muscle myopathic changes or if it could reflect the cardiac phenotype, thus representing a biomarker of cardiac involvement.

We have analyzed skeletal muscle from DM1 and DM2 patients with cardiac involvement (CI) or without cardiac involvement (NCI). In DM1 patients, both proximal and distal muscles have been considered since it is known that these muscles are differently affected in this pathology, thus affecting their suitability for biomarker discovery ([@B47]). As expected, among DM1, the global histopathological alterations appear to be more compromised in the TA muscle than in the BB muscles. Moreover, patients of CI subgroups present muscles globally more compromised than those of NCI subgroups, indicating that cardiac involvement increased as the muscular disease became aggravated.

cTnT is considered a marker of skeletal muscle regeneration since, when it is injured, it repairs itself by a process that recapitulates embryonic myogenesis and causes re-expression of several fetal proteins, including cTnT and fetal myosin isoforms ([@B31]). Among all the muscles examined in our study, the highest levels of *TNNT2* total mRNA expression and the higher percentage of fibers expressing MHC-emb or MHC-neo have been observed in regenerating muscles of noDM-IBM patients. In our cohort of DM patients, a clear increase of *TNNT2* expression has been observed in DM1 TA muscles. Moreover, a significant correlation between the *TNNT2* mRNA expression levels and the percentage of MHC-neo positive fibers is present when considering either all the muscle samples analyzed or the DM cohort, and this correlation is more evident in DM1 TA muscles, confirming that this gene is more expressed in skeletal muscle expressing fetal myosins. On the contrary, no correlation is evident in DM2 patients. Nevertheless, DM skeletal muscle is not considered a regenerating tissue since it does not show the typical histological features of regenerating muscle reported in other types of muscular dystrophies. Moreover, a very low number of MHC-emb positive fibers and few MHC-neo positive fibers are observable in both DM1 (BB and TA) and DM2 muscles compared to the regenerating noDM-IBM muscles. Also, almost all fibers with central nuclei resulted negative to MHC-neo or MHC-emb immunostaining, and like many myopathies, centrally positioned nuclei in DM seem not to be linked to degeneration/regeneration processes ([@B48]). It is noteworthy that when considering the global muscle alteration using the histopathological score described in Materials and Methods, a significant correlation with cTnT expression is evident when considering all DM muscles examined or DM1 TA muscles. Taken together, these results suggest that the typical histological alterations observable in DM skeletal muscles may not be related to a degeneration/regeneration process; however, the myopathic changes in the most severely affected muscles can lead to a slight reexpression of cTnT. Nevertheless, in our western blot experiments, the antibody used detects positive bands at a molecular weight consistent with cTnT in the skeletal muscle of noDM-IBM patients and in the myocardium, but no bands have been detected in any of the DM or CTR skeletal muscles. Our data are in line with those reported by other authors on cTnT protein expression in regenerating muscles and suggest that, in DM skeletal muscle, a very low or no expression of cTnT protein is present ([@B32], [@B34], [@B35], [@B49], [@B50]). These data open the question of the biological significance of the elevated circulating cTnT found in DM patients without clinical cardiovascular disease ([@B33], [@B34]). Increased plasma cTnT levels in DM patients might be caused by subclinical myocardial damage not detected by conventional measures rather than to a release of cTnT protein from injured skeletal muscle into the circulation as observed in various neuromuscular diseases included IBM disease ([@B32], [@B33]). However, our data and recently reported data suggest that cTnT antibodies detect positive bands at a molecular weight corresponding to skeletal muscle TnT in both healthy and diseased muscle, indicating that a cross-reactivity with the skeletal muscle TnT may contribute to elevated cTnT plasma concentrations in patients with myopathies ([@B51], [@B52]).

It is known that *TNNT2* alternative splicing is disrupted in DM and in other neuromuscular diseases such that exon 5 is inappropriately included in adult skeletal muscle ([@B25], [@B36], [@B45]). Several studies on human patients and mouse models of muscular dystrophies report that splicing changes may be a much more general phenomenon of muscle disease and can be secondary to muscle regeneration ([@B44], [@B45], [@B53]). In order to verify this hypothesis in DM skeletal muscles, we have analyzed the DM-associated splicing defects of *TNNT2* and of several genes involved in DM skeletal muscle histological and physiological alterations. When considering the alternative splicing of muscle-specific genes, the expression of the aberrant isoforms significantly correlates with the muscle histopathological alterations. Indeed, among BB muscles, missplicing of the skeletal muscle-specific genes is more evident in DM2 patients and appears to be higher in patient groups who also present more severe muscle histopathological alterations. Moreover, the extent of splicing alterations in DM1 TA distal skeletal muscles is greater compared to that observed in DM1 BB, and it appears to be similar in the two DM1 subgroups who also show similar muscular histopathological alterations. These data confirm what was already reported by other authors in that proximal muscles are less involved than distal muscles in DM1, thus affecting their suitability for biomarker discovery ([@B47], [@B54]). However, despite the marked regenerative process, our IBM muscles do not express greater levels of DM-specific pathological isoforms of the muscle-specific genes than those observed in CTR, except for *RYR1*. The altered splicing of *RYR1* could explain the recent data by Amici et al. ([@B55]) who reported a lower protein expression of RyR1 in IBM muscles as compared to healthy subjects, indicating that Ca^2+^ dysregulation may contribute to muscle weakness and atrophy in this myopathy. We therefore can speculate that the splicing alterations of the skeletal muscle-specific genes observed in DM might not occur only secondary to an active remodeling process with myopathic changes but they could be effectively important in DM skeletal muscle pathology. These data are in line with those previously reported in other works ([@B9], [@B13], [@B47], [@B56], [@B57]).

When considering the *TNNT2* gene, missplicing appears to be more evident in DM1 muscles than in DM2 or noDM-IBM muscles. Indeed, despite the fact that proximal muscles are more involved in DM2 than in DM1 patients ([@B47], [@B54]), contrary to DM1, in DM2 BB, the *TNNT2* fetal isoform appears to be less expressed than the adult isoform. However, this evidence does not seem to be related to less severe histopathological alterations since the results of the quantitative evaluation of histopathological parameters appear to be similar in DM1 BB and DM2 BB muscles. Also, in regenerating muscle of noDM-IBM patients, a weak increase of the fetal isoform expression is present compared to CTR; however, the adult isoform is the prevalent isoform expressed in these muscles. These data seem to indicate that the more severe *TNNT2* missplicing observed in DM1 compared to the other muscles analyzed could not be related only to myopathic changes but could reflect the more severe general phenotype compared to DM2, including cardiac problems that appear to be more severe and frequent in patients with DM1 than in patients with DM2 ([@B19]). In order to verify if the more severe *TNNT2* missplicing observed in DM1 muscle could reflect a more severe cardiac involvement, the expression of *TNNT2* fetal isoform has been correlated to cardiac parameters obtained by ECG, ECG-Holter, or echocardiogram. The results of this analysis show that when considering all DM patients, *TNNT2* missplicing significantly correlates with the QRS cardiac parameter, and this correlation is evident in DM1 but not in DM2 patients. Of interest, the significant correlation is present also when considering the DM1-CI subgroups. This result is of particular interest since it has been reported that the gradual prolongation of QRS duration in patients affected by DM suggests the contribution of progressive fibrosis to conduction delay in this disease ([@B58]). Taken together, these results seem to indicate that the expression levels of the *TNNT2* fetal isoform could reflect the general phenotype including the cardiac involvement of DM1 but not of DM2 patients. It is known that different pathomolecular mechanisms may contribute to the lesser severity of DM2 compared to DM1. Recently, it has been reported that the rbFOX proteins may participate to the lesser toxicity of the CCTG repeat expansion in DM2 since they compete with and reduce the titration of MBNL1 within CCUG but not within CUG RNA foci ([@B59]).

The results of our study do not allow us to conclude that *TNNT2* missplicing may be considered a specific cardiac biomarker in adult skeletal muscle of DM1 patients and further investigations will be necessary to support this hypothesis. However, our data suggest that this splicing event has good potential to function as a biomarker of DM1 severity, and it should be considered in pharmacological clinical trials to monitor the possible effects of different therapeutic approaches on muscle tissues.

There are two important limitations to be acknowledged in the present study. The first limitation is the study cohort\'s limited sample size in some subgroups that is due to the rareness of these pathologies; thus, our evidences may not be conclusive. A second limitation regards the cardiac data taken into account. Indeed, only echocardiographic data on myocardial structure have been considered in the study, and probably, cardiac MRI data could be useful to identify the presence of myocardial morphological alterations since it is a more accurate and highly reproducible technique for assessment of cardiac volumes, function, mass, and fibrosis.
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